Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 6, 2024Journal of Clinical MedicineOpen Access

A Systemic Immune Inflammation Index and PD-L1 (SP142) Expression as a Potential Combined Biomarker of the Clinical Benefit of Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJong Min BaekYeouido St. Mary's HospitalHCHyungkeun ChaInha University HospitalYMYeonsook MoonInha University Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Baek et al. (2024) studied this question.

synapsesocial.com/papers/68e7579cb6db6435876cede7https://doi.org/10.3390/jcm13051521
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis2014 · 3,397 citations
  2. 2Hallmarks of Cancer: The Next Generation2011 · 68,085 citations
  3. 3PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers2019 · 556 citations
  4. 4Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen–Induced Lung Cancer and Determines the Efficacy of Immunotherapy2020 · 115 citations
  5. 5A Novel Score Using Lymphocyte-to-Monocyte Ratio in Blood and Malignant Body Fluid for Predicting Prognosis of Patients with Advanced Ovarian Cancer2023 · 5 citations